JP2010524486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524486A5 JP2010524486A5 JP2010504745A JP2010504745A JP2010524486A5 JP 2010524486 A5 JP2010524486 A5 JP 2010524486A5 JP 2010504745 A JP2010504745 A JP 2010504745A JP 2010504745 A JP2010504745 A JP 2010504745A JP 2010524486 A5 JP2010524486 A5 JP 2010524486A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomer
- cancer
- seq
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060000903 Beta-catenin Proteins 0.000 claims 7
- 239000000178 monomer Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 102000015735 Beta-catenin Human genes 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91537107P | 2007-05-01 | 2007-05-01 | |
| US2324408P | 2008-01-24 | 2008-01-24 | |
| PCT/EP2008/055365 WO2008132234A2 (en) | 2007-05-01 | 2008-04-30 | Rna antagonist compounds for the modulation of beta-catenin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014125205A Division JP2014209915A (ja) | 2007-05-01 | 2014-06-18 | β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010524486A JP2010524486A (ja) | 2010-07-22 |
| JP2010524486A5 true JP2010524486A5 (enExample) | 2011-07-14 |
Family
ID=39926160
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504745A Pending JP2010524486A (ja) | 2007-05-01 | 2008-04-30 | β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 |
| JP2014125205A Abandoned JP2014209915A (ja) | 2007-05-01 | 2014-06-18 | β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014125205A Abandoned JP2014209915A (ja) | 2007-05-01 | 2014-06-18 | β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20090005335A1 (enExample) |
| EP (1) | EP2152879B1 (enExample) |
| JP (2) | JP2010524486A (enExample) |
| KR (1) | KR20100024399A (enExample) |
| CN (1) | CN101842483A (enExample) |
| AU (1) | AU2008244211B2 (enExample) |
| CA (1) | CA2685444A1 (enExample) |
| DK (1) | DK2152879T3 (enExample) |
| EA (1) | EA018986B1 (enExample) |
| ES (1) | ES2399371T3 (enExample) |
| IL (1) | IL201865A0 (enExample) |
| MX (1) | MX2009011878A (enExample) |
| NZ (1) | NZ581200A (enExample) |
| TW (1) | TW200848077A (enExample) |
| WO (1) | WO2008132234A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2152879T3 (da) * | 2007-05-01 | 2013-02-18 | Santaris Pharma As | RNA antagonistforbindelser til modulering af beta-catenin |
| EP2490767A4 (en) * | 2009-07-15 | 2013-02-13 | Santaris Pharma As | OBJECTIVE RNA ANTAGONISTS FOR THE TREATMENT OF LEUKEMIA ON GLI2 |
| DK2591105T3 (en) | 2010-07-06 | 2017-07-31 | Dicerna Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF BETA-CATENIN USING DOUBLE-STRENGTH RNA |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| US20140323557A1 (en) * | 2011-11-11 | 2014-10-30 | Santaris Pharma A/S | Compounds for the modulation of beta-catenin expression and uses thereof |
| BR112014016870A2 (pt) | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
| CN104583398A (zh) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节基因表达的组合物和方法 |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| CN104583402A (zh) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节mecp2表达的组合物和方法 |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| CA2893801A1 (en) * | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| JP2016518842A (ja) | 2013-05-01 | 2016-06-30 | レグルス セラピューティクス インコーポレイテッド | マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法 |
| EP2992096B1 (en) | 2013-05-01 | 2021-03-03 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| WO2015026346A1 (en) | 2013-08-22 | 2015-02-26 | Hewlett Packard Development Company, L.P. | Projective computing system |
| TWI657755B (zh) * | 2013-12-30 | 2019-05-01 | Philip Morris Products S. A. | 包含隔熱可燃熱源之煙品 |
| JP2017506259A (ja) | 2014-02-03 | 2017-03-02 | イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． | 幹細胞を枯渇させるためのカゼインキナーゼｉ阻害剤の使用 |
| WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
| US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
| US11643655B2 (en) * | 2016-11-15 | 2023-05-09 | City Of Hope | Methods for intracellular delivery and enhanced gene targeting |
| EP3579890B1 (en) | 2017-02-09 | 2025-06-18 | Femasys Inc. | Methods and compositions comprising biodegradable cyanoacrylates |
| TWI854980B (zh) | 2018-05-08 | 2024-09-11 | 美商雷格勒斯治療公司 | 用於調節mir-122之微小rna化合物及方法 |
| EP4441224A4 (en) * | 2021-12-03 | 2026-03-11 | Quralis Corp | Antisense oligonucleotides with modified skeletal chemicals |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US6066500A (en) | 1999-06-25 | 2000-05-23 | Isis Pharmaceuticals Inc. | Antisense modulation of Beta catenin expression |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US20030064384A1 (en) * | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
| US20030143586A1 (en) | 2001-10-12 | 2003-07-31 | Qimin Chao | Genetic hypermutability of plants for gene discovery and diagnosis |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| AU2004230927B9 (en) | 2003-04-13 | 2011-12-01 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
| US20050136395A1 (en) * | 2003-05-08 | 2005-06-23 | Affymetrix, Inc | Methods for genetic analysis of SARS virus |
| US20070009899A1 (en) * | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CA2622583A1 (en) | 2005-09-15 | 2007-03-22 | Henrik Frydenlund Hansen | Rna antagonist compounds for the inhibition of apo-b100 expression |
| EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| WO2008034122A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| CA2662520A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| WO2008053314A2 (en) | 2006-10-30 | 2008-05-08 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| DK2152879T3 (da) | 2007-05-01 | 2013-02-18 | Santaris Pharma As | RNA antagonistforbindelser til modulering af beta-catenin |
-
2008
- 2008-04-30 DK DK08749943.0T patent/DK2152879T3/da active
- 2008-04-30 CN CN200880022871A patent/CN101842483A/zh active Pending
- 2008-04-30 NZ NZ581200A patent/NZ581200A/en not_active IP Right Cessation
- 2008-04-30 MX MX2009011878A patent/MX2009011878A/es active IP Right Grant
- 2008-04-30 WO PCT/EP2008/055365 patent/WO2008132234A2/en not_active Ceased
- 2008-04-30 KR KR1020097025006A patent/KR20100024399A/ko not_active Ceased
- 2008-04-30 EA EA200971013A patent/EA018986B1/ru not_active IP Right Cessation
- 2008-04-30 EP EP08749943A patent/EP2152879B1/en active Active
- 2008-04-30 CA CA002685444A patent/CA2685444A1/en not_active Abandoned
- 2008-04-30 JP JP2010504745A patent/JP2010524486A/ja active Pending
- 2008-04-30 US US12/113,031 patent/US20090005335A1/en not_active Abandoned
- 2008-04-30 ES ES08749943T patent/ES2399371T3/es active Active
- 2008-04-30 TW TW097116039A patent/TW200848077A/zh unknown
- 2008-04-30 AU AU2008244211A patent/AU2008244211B2/en not_active Ceased
-
2009
- 2009-01-21 US US12/356,923 patent/US7915401B2/en not_active Expired - Fee Related
- 2009-11-01 IL IL201865A patent/IL201865A0/en unknown
-
2010
- 2010-09-02 US US12/874,668 patent/US8039446B2/en not_active Expired - Fee Related
-
2011
- 2011-09-14 US US13/232,123 patent/US20120004288A1/en not_active Abandoned
-
2014
- 2014-06-18 JP JP2014125205A patent/JP2014209915A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10041074B2 (en) | Euchromatic region targeting methods for modulating gene expression | |
| KR101878587B1 (ko) | 올리고머 및 올리고머 접합체 | |
| JP2022036182A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| KR102028784B1 (ko) | 유전자 발현을 조절하기 위한 조성물 및 방법 | |
| ES2837437T3 (es) | Usos diagnósticos, pronósticos y terapéuticos de ARN largos no codificantes para cardiopatías y medicina regenerativa | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| EA015570B1 (ru) | Фармацевтическая композиция | |
| US8039446B2 (en) | Compounds for the modulation of beta-catenin expression | |
| Zhang et al. | RETRACTED: Comprehensive review for non-coding RNAs: From mechanisms to therapeutic applications | |
| WO2014025887A1 (en) | Selective reactivation of genes on the inactive x chromosome | |
| AU2017224226A1 (en) | Compositions and methods of using piRNAs in cancer diagnostics and therapeutics | |
| JP2010526797A5 (enExample) | ||
| JP2014509512A (ja) | オリゴマーの増強された体内分布 | |
| TW200908987A (en) | RNA antagonist compounds for the modulation of HER3 | |
| TW200927176A (en) | RNA antagonist compounds for the modulation of PIK3CA expression | |
| BR122020018622A2 (pt) | Molécula de ácido nucleico para redução de papd5 e papd7 de mrna para o tratamento de infecção hepatite b | |
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| Moccia et al. | Structural insights on tiny peptide nucleic acid (PNA) analogues of miRNA-34a: An in silico and experimental integrated approach | |
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| EP4077670A1 (en) | Use of cops3 inhibitors for treating hepatitis b virus infection | |
| CN114829601A (zh) | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| CN107988230A (zh) | 抑制NOB1基因的siRNA分子 | |
| CN108192895A (zh) | 靶向NOB1基因的siRNA分子及其应用 | |
| HK40071185A (en) | Use of sept9 inhibitors for treating hepatitis b virus infection | |
| WO2022196668A1 (ja) | Ｉｔｇａｖを標的とする核酸医薬 |